# A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors

> **NCT03264066** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 87 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Cobimetinib
- **DRUG:** Atezolizumab
- **DRUG:** Atezolizumab Cohort 7

## Key facts

- **NCT ID:** NCT03264066
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-23
- **Primary completion:** 2020-06-25
- **Final completion:** 2020-06-25
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2021-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03264066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03264066, "A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03264066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*